Roth Capital initiated coverage of Annovis Bio with a Buy rating and $8 price target. The firm is bullish on the company's Alzheimer's disease program based on Buntanetap's safety profile/oral route, unique mechanism of action targeting multiple neurotoxic proteins, evidence of cognitive benefit and biomarker engagement, and potential for asymmetric reward upon positive Phase 3 results in the first half of 2027.
